This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 3
  • /
  • Update on COVID-19 variants and impact on bamlaniv...

Update on COVID-19 variants and impact on bamlanivimab distribution.

Read time: 1 mins
Published:27th Mar 2021
The Assistant Secretary for Preparedness and Response (ASPR) and the FDA within the U.S. Department of Health and Human Services reported that given the sustained increase in SARS-CoV-2 viral variants in the United States that are resistant to bamlanivimab administered alone, and the availability of other authorized monoclonal antibody therapies that are expected to retain activity to these variants, the U.S. Government, in coordination with Eli Lilly and Company, will stop the distribution of bamlanivimab alone starting March 24, 2021. Bamlanivimab, can still work if used in combination with etesevimab..The FDA in February 2021 approved this combination for emergency use in recently diagnosed patients at high risk for COVID-19 complications.
Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.